Literature DB >> 14664796

Transfection of airway epithelium by stable PEGylated poly-L-lysine DNA nanoparticles in vivo.

Assem-Galal Ziady1, Christopher R Gedeon, Timothy Miller, William Quan, Jennifer M Payne, Susannah L Hyatt, Tamara L Fink, Osman Muhammad, Sharon Oette, Tomasz Kowalczyk, Murali K Pasumarthy, Robert C Moen, Mark J Cooper, Pamela B Davis.   

Abstract

DNA can be compacted using polyethylene glycol-substituted poly-L-lysine into discrete unimolecular (with respect to DNA) nanoparticles with minor diameter < 20 nm that are stable in normal saline for at least 23 months at 4 degrees C. We compared the activity of firefly luciferase in lungs of C57BL/6 mice that received 100 microg compacted plasmid in 25 microl saline (shown to be the optimal dose) via intratracheal or intranasal instillation with levels in animals given 100 microg naked plasmid or in untreated mice. Mice dosed with compacted DNA nanoparticles had peak activity of luciferase in lung at 2 days postinstillation, which declined in log-linear fashion with a half-life of 1.4 days. Luciferase activity in animals dosed with naked DNA was 200-fold less. Addition of polyethylene glycol to the complex was necessary for efficient gene transfer and animals that received DNA compacted with unmodified poly-L-lysine did not exhibit luciferase activity above background. Immunohistochemical staining for bacterial beta-galactosidase 2 days after administration of a compacted lacZ expression plasmid (n = 8) revealed expression predominantly in the dependent portions of the right lungs of mice, in alveolar and airway epithelial cells, though macrophages and sometimes endothelial cells also were transfected. No staining for beta-galactosidase was observed in uninjected animals (n = 4) or those dosed with naked lacZ plasmid (n = 7). Tissue survey for transgene expression shows expression only in lung and trachea following intranasal administration. Stable compacted DNA nanoparticles transfer exogenous genes to airway epithelium and show promise for lung gene therapy.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14664796     DOI: 10.1016/j.ymthe.2003.07.007

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  62 in total

Review 1.  Nanoparticles for retinal gene therapy.

Authors:  Shannon M Conley; Muna I Naash
Journal:  Prog Retin Eye Res       Date:  2010-05-07       Impact factor: 21.198

2.  Non-degradative intracellular trafficking of highly compacted polymeric DNA nanoparticles.

Authors:  Anthony J Kim; Nicholas J Boylan; Jung Soo Suk; Samuel K Lai; Justin Hanes
Journal:  J Control Release       Date:  2011-10-30       Impact factor: 9.776

3.  Reducible DNA nanoparticles enhance in vitro gene transfer via an extracellular mechanism.

Authors:  Wenchao Sun; Pamela B Davis
Journal:  J Control Release       Date:  2010-05-12       Impact factor: 9.776

4.  Transgene expression in the striatum following intracerebral injections of DNA nanoparticles encoding for human glial cell line-derived neurotrophic factor.

Authors:  A M Fletcher; T H Kowalczyk; L Padegimas; M J Cooper; D M Yurek
Journal:  Neuroscience       Date:  2011-08-04       Impact factor: 3.590

5.  Optimization of hCFTR lung expression in mice using DNA nanoparticles.

Authors:  Linas Padegimas; Tomasz H Kowalczyk; Sam Adams; Chris R Gedeon; Sharon M Oette; Karla Dines; Susannah L Hyatt; Ozge Sesenoglu-Laird; Olena Tyr; Robert C Moen; Mark J Cooper
Journal:  Mol Ther       Date:  2011-09-27       Impact factor: 11.454

Review 6.  Cell and gene therapy for genetic diseases: inherited disorders affecting the lung and those mimicking sudden infant death syndrome.

Authors:  Allison M Keeler; Terence R Flotte
Journal:  Hum Gene Ther       Date:  2012-06       Impact factor: 5.695

Review 7.  Nanoparticle applications in ocular gene therapy.

Authors:  Xue Cai; Shannon Conley; Muna Naash
Journal:  Vision Res       Date:  2007-09-06       Impact factor: 1.886

8.  DNA nanoparticle-mediated thymulin gene therapy prevents airway remodeling in experimental allergic asthma.

Authors:  Adriana L da Silva; Sabrina V Martini; Soraia C Abreu; Cynthia dos S Samary; Bruno L Diaz; Sandra Fernezlian; Vanessa Karen de Sá; Vera Luiza Capelozzi; Nicholas J Boylan; Rodolfo Gustavo Goya; Jung Soo Suk; Patricia R M Rocco; Justin Hanes; Marcelo M Morales
Journal:  J Control Release       Date:  2014-02-17       Impact factor: 9.776

9.  Non-covalent ligand conjugation to biotinylated DNA nanoparticles using TAT peptide genetically fused to monovalent streptavidin.

Authors:  Wenchao Sun; David Fletcher; Rolf Christiaan van Heeckeren; Pamela B Davis
Journal:  J Drug Target       Date:  2012-09       Impact factor: 5.121

Review 10.  Barriers to inhaled gene therapy of obstructive lung diseases: A review.

Authors:  Namho Kim; Gregg A Duncan; Justin Hanes; Jung Soo Suk
Journal:  J Control Release       Date:  2016-05-16       Impact factor: 9.776

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.